Abstract
The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Omalizumab inhibits allergic responses by binding to serum immunoglobulins E (IgE), thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of down-regulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both peripheral blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Moreover, some recent studies suggest potential benefits of omalizumab also in non allergic phenotypes of severe asthma. Very interesting are also further recent reports referring to the potential inhibitory effect of omalizumab with regard to bronchial structural changes, especially occurring in severe asthma and globally defined as airway remodeling. Omalizumab is relatively well tolerated, and only very rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent asthma, inadequately controlled by high doses of standard inhaled treatments.
Keywords: Anti-IgE, omalizumab, severe asthma.
Current Drug Targets
Title:Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments
Volume: 16 Issue: 2
Author(s): Girolamo Pelaia, Alessandro Vatrella, Maria Teresa Busceti, Luca Gallelli, Rosa Terracciano and Rosario Maselli
Affiliation:
Keywords: Anti-IgE, omalizumab, severe asthma.
Abstract: The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Omalizumab inhibits allergic responses by binding to serum immunoglobulins E (IgE), thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of down-regulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both peripheral blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Moreover, some recent studies suggest potential benefits of omalizumab also in non allergic phenotypes of severe asthma. Very interesting are also further recent reports referring to the potential inhibitory effect of omalizumab with regard to bronchial structural changes, especially occurring in severe asthma and globally defined as airway remodeling. Omalizumab is relatively well tolerated, and only very rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent asthma, inadequately controlled by high doses of standard inhaled treatments.
Export Options
About this article
Cite this article as:
Pelaia Girolamo, Vatrella Alessandro, Teresa Busceti Maria, Gallelli Luca, Terracciano Rosa and Maselli Rosario, Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450116666141219122157
DOI https://dx.doi.org/10.2174/1389450116666141219122157 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Perspectives in Integrin Blocking (Executive Editor: C. Marcinkiewicz)]
Current Pharmaceutical Design Malononitrile as a Key Reagent in Multicomponent Reactions for the Synthesis of Pharmaceutically Important Pyridines
Current Organic Chemistry Exhaled Breath Condensate in Asthma: From Bench to Bedside
Current Medicinal Chemistry The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry Isoform Selective Phosphoinositide 3-Kinase γ and δ Inhibitors and Their Therapeutic Potential
Recent Patents on Inflammation & Allergy Drug Discovery Clinical Significance and Evaluation of Polysensitisation Using Skin Sensitisation Profiling in Atopic Dermatitis
Inflammation & Allergy - Drug Targets (Discontinued) Chemical Constituents and Biological Activities of Cordia myxa L.: A Review
The Natural Products Journal New Patents of Fixed Combinations of Nasal Antihistamines and Corticosteroids in Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Current Anti-Inflammatory Therapies and the Potential of Secretory Phospholipase A2 Inhibitors in the Design of New Anti-Inflammatory Drugs: A Review of 2012 - 2018
Current Medicinal Chemistry Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Regulation of Apoptosis by SYB in HepG2 Liver Cancer Cells is Mediated by the P53/Caspase 9 Axis
Anti-Cancer Agents in Medicinal Chemistry An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases
Current Respiratory Medicine Reviews Microbiota Regulation of Inflammatory Bowel Disease
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Hot Topic: Recent Advances and Future Prospect in Protease Targeting (Executive Editor: B. Turk) ]
Current Pharmaceutical Design Antioxidants and Mucolytics in COPD Management: When (if ever) and in Whom?
Current Drug Targets Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities
Current Pharmaceutical Biotechnology Meet Our Associate Editor
Applied Clinical Research, Clinical Trials and Regulatory Affairs PDE-5 Inhibitors: Clinical Points
Current Drug Targets CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions
Current Pharmaceutical Design Cytokines in Candidiasis and Aspergillosis
Current Pharmaceutical Biotechnology